

Please amend the application as follows:

In the Specification

At page 1, lines 4-10, please delete the substance of the Related Applications paragraph and insert therefor:

---This application is the U.S. National Phase of PCT/US96/02153, filed February 12, 1996 and is a continuation-in-part of U.S. Serial No. 08/523,004 (Attorney Docket No. LKS94-04A), filed on September 1, 1995, which is a continuation-in-part of U.S. Serial No. 08/386,857 (Attorney Docket No. LKS94-04), filed on February 10, 1995, the teachings of which are each incorporated herein by reference in their entirety.

An Abstract of the Disclosure on a separate sheet (page 131) is provided herewith. Please add the abstract to the application following the claims.

In the Claims

Please cancel Claim 27 and amend Claims 24, 25 and 28 as follows:

24. (Amended) A fusion protein comprising a naturally occurring primate MAdCAM.
25. (Amended) The fusion protein of Claim 24, comprising a first moiety and a second moiety, wherein said first moiety is a naturally occurring primate MAdCAM and said second moiety is at least a portion of an immunoglobulin chain [or variant thereof].
28. (Amended) The fusion protein of Claim 25, wherein the second moiety is at least a portion of an immunoglobulin heavy chain constant region [or variant thereof].

Please add new Claims 101-135.

- 101. The fusion protein of Claim 24, comprising a first moiety and a second moiety, wherein said first moiety is a naturally occurring primate MAdCAM and said second moiety is at least a portion of a mutant immunoglobulin chain, said mutant having reduced binding affinity for Fc receptor and/or complement relative to wild type immunoglobulin.